Genital herpes is an infection of the genitals, buttocks, or anal area caused by herpes simplex virus (HSV).

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

1 Tony Wood, Chief Scientific Officer at GSK, said: “We welcome this positive recommendation that can help strengthen disease prevention efforts in the US. Pentavalent vaccines can reduce the ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for ...

GSK has garnered FDA ... has previously said that the vaccine is one of its most important product launches for 2025, with the potential to make $1 billion to $2 billion in sales at its peak.

GlaxoSmithKline recently held a high-level scientific conference in conjunction with the launch of “Bexsero,” the first vaccine in Egypt approved by the Egyptian Drug Authority for the ...

With the GSK share price at 1,317.5p today, the group is valued at £54.3bn. This stock trades on 21.2 times earnings and offers a market-beating dividend yield of 4.6% a year. These fundamentals ...